Skip to main content
Clinical Trials/NL-OMON48828
NL-OMON48828
Completed
Not Applicable

Predicting Treatment Resistance in Schizophrenia - TREVOS

Academisch Medisch Centrum0 sites120 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
first episode psychosis
Sponsor
Academisch Medisch Centrum
Enrollment
120
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • For patients:
  • \- First episode psychosis
  • \- Age 18\-35 years old;For healthy contols:
  • \- Age 18\-35 years old

Exclusion Criteria

  • \- Antipsychotic use longer than one year
  • \- Dependence on other substances of abuse than nicotine or cannabis
  • \- Use of amphetamine, cocaine or medication for ADHD (attention deficit hyperactivity disorder), since these drugs influence the dopamine system
  • \- Neurological disorder (e.g. epilepsy) or evidence of brain damage
  • \- Inability to provide informed consent;In addition to the exclusion criteria mentioned above, healthy control subjects are not allowed to have any kind of psychiatric disorder;Exclusion criteria directly related to MRI scanning:
  • \- Contra\-indications for MRI (including pacemaker, ferromagnetic implants, claustrophobia)
  • \- Pregnancy;Exclusion criteria directly related to PET/CT scanning (for subgroup of 40 patients):
  • \- Participation in a scientific examination where radiation was used, in the last year.
  • \- Positive urine drug screen on the day of the PET/CT scan. Participants will be tested on cannabis, amphetamine, XTC, cocaine and opiates. Only recent cannabis use will be accepted.
  • \- In women: positive pregnancy test on the day of the PET/CT scan and lactation.

Outcomes

Primary Outcomes

Not specified

Similar Trials